NCT03511560 - Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

July 17, 2020

Study Completion Date

July 17, 2021

Conditions

Renal Transplant RejectionKidney Transplant Failure and Rejection

Interventions

DRUG

Tacrolimus Extended Release Oral Tablet

Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.

DRUG

Tacrolimus

Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician

Trial Locations (1)

10032

Columbia University Medical Center, New York